Two decades after BRCA: Setting paradigms in personalized cancer care and prevention

Fergus J Couch, Katherine L. Nathanson, Kenneth Offit

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1, BRCA2, and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2, the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.

Original languageEnglish (US)
Pages (from-to)1466-1470
Number of pages5
JournalScience
Volume343
Issue number6178
DOIs
StatePublished - 2014

Fingerprint

Mutation
Paradigm
Cancer
Gene
Breast Cancer
Susceptibility
Cloning
Genetic Testing
Screening
Therapy

ASJC Scopus subject areas

  • General
  • History and Philosophy of Science

Cite this

Two decades after BRCA : Setting paradigms in personalized cancer care and prevention. / Couch, Fergus J; Nathanson, Katherine L.; Offit, Kenneth.

In: Science, Vol. 343, No. 6178, 2014, p. 1466-1470.

Research output: Contribution to journalArticle

Couch, Fergus J ; Nathanson, Katherine L. ; Offit, Kenneth. / Two decades after BRCA : Setting paradigms in personalized cancer care and prevention. In: Science. 2014 ; Vol. 343, No. 6178. pp. 1466-1470.
@article{826453aa0ea142e1aa3acf2141856207,
title = "Two decades after BRCA: Setting paradigms in personalized cancer care and prevention",
abstract = "The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1, BRCA2, and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2, the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.",
author = "Couch, {Fergus J} and Nathanson, {Katherine L.} and Kenneth Offit",
year = "2014",
doi = "10.1126/science.1251827",
language = "English (US)",
volume = "343",
pages = "1466--1470",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6178",

}

TY - JOUR

T1 - Two decades after BRCA

T2 - Setting paradigms in personalized cancer care and prevention

AU - Couch, Fergus J

AU - Nathanson, Katherine L.

AU - Offit, Kenneth

PY - 2014

Y1 - 2014

N2 - The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1, BRCA2, and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2, the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.

AB - The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1, BRCA2, and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2, the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.

UR - http://www.scopus.com/inward/record.url?scp=84896995635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896995635&partnerID=8YFLogxK

U2 - 10.1126/science.1251827

DO - 10.1126/science.1251827

M3 - Article

C2 - 24675953

AN - SCOPUS:84896995635

VL - 343

SP - 1466

EP - 1470

JO - Science

JF - Science

SN - 0036-8075

IS - 6178

ER -